173 related articles for article (PubMed ID: 35166240)
21. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
22. The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming.
Mansour AA; Gafni O; Weinberger L; Zviran A; Ayyash M; Rais Y; Krupalnik V; Zerbib M; Amann-Zalcenstein D; Maza I; Geula S; Viukov S; Holtzman L; Pribluda A; Canaani E; Horn-Saban S; Amit I; Novershtern N; Hanna JH
Nature; 2012 Aug; 488(7411):409-13. PubMed ID: 22801502
[TBL] [Abstract][Full Text] [Related]
23. Deciding on the therapy of multiple myeloma using genetic risk stratification.
Gertz MA
Leuk Lymphoma; 2011 Feb; 52(2):157-8. PubMed ID: 21261501
[No Abstract] [Full Text] [Related]
24. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
[TBL] [Abstract][Full Text] [Related]
25. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
26. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.
Onwuazor ON; Wen XY; Wang DY; Zhuang L; Masih-Khan E; Claudio J; Barlogie B; Shaughnessy JD; Stewart AK
Blood; 2003 Jul; 102(2):772-3. PubMed ID: 12835230
[No Abstract] [Full Text] [Related]
27. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
Licht JD
Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
[TBL] [Abstract][Full Text] [Related]
28. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
[TBL] [Abstract][Full Text] [Related]
29. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
30. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
31. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
[TBL] [Abstract][Full Text] [Related]
32. Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo.
Dal-Pra S; Hodgkinson CP; Mirotsou M; Kirste I; Dzau VJ
Circ Res; 2017 Apr; 120(9):1403-1413. PubMed ID: 28209718
[TBL] [Abstract][Full Text] [Related]
33. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
34. Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.
Puig N; Trudel S; Keats JJ; Li ZH; Braggio E; Ahmann GJ; Zeng S; Fonseca R; Kukreti V
J Clin Oncol; 2009 Nov; 27(33):e194-7. PubMed ID: 19805681
[No Abstract] [Full Text] [Related]
35. Dutcher bodies in multiple myeloma are highly associated with translocation t(4;14) and IgA isotype.
Jiang N; Qi C; Chang H
Br J Haematol; 2015 Dec; 171(5):890-2. PubMed ID: 25907777
[No Abstract] [Full Text] [Related]
36. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
37. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
Richelda R; Ronchetti D; Baldini L; Cro L; Viggiano L; Marzella R; Rocchi M; Otsuki T; Lombardi L; Maiolo AT; Neri A
Blood; 1997 Nov; 90(10):4062-70. PubMed ID: 9354676
[TBL] [Abstract][Full Text] [Related]
38. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
39. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
40. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
